Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
J., Schoonover, K
KLOW peptide is a four-component research blend BPC-157 (50mg), TB-500 (10mg), KPV (10mg), GHK-Cu (10mg) 80mg total in a 3mL lyophilized vial
The 2009 Venkova paper anchored the rodent-model postoperative-ileus framing (PMID 19289567)
U54HD061221), which is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through collaboration between the Office of Rare Diseases Research (ORDR), the National Center for Advancing Translational Science (NCATS) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and NIH K08DK106453
However, because BPC-157 and TB-500 promote angiogenesis (new blood vessel formation) and healing, theoretical concerns exist about providing blood supply to existing tumors
